Inhibrx Biosciences (NASDAQ:INBX) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Inhibrx Biosciences (NASDAQ:INBX – Free Report) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

INBX has been the topic of several other research reports. HC Wainwright cut their price target on Inhibrx Biosciences from $245.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Friday, September 11th. Finally, Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.00.

Check Out Our Latest Research Report on INBX

Inhibrx Biosciences Stock Performance

INBX opened at $68.97 on Friday. Inhibrx Biosciences has a one year low of $57.30 and a one year high of $155.29. The stock has a market capitalization of $1.02 billion, a P/E ratio of -7.61 and a beta of 4.03. The business’s 50-day simple moving average is $91.17 and its 200-day simple moving average is $92.01.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($2.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The company had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $1.90 million. On average, equities research analysts forecast that Inhibrx Biosciences will post -9.70 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Mark Lappe acquired 25,000 shares of Inhibrx Biosciences stock in a transaction on Tuesday, September 8th. The stock was purchased at an average cost of $105.82 per share, with a total value of $2,645,500.00. Following the purchase, the chief executive officer directly owned 730,548 shares in the company, valued at approximately $77,306,589.36. The trade was a 3.54% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kimberly Manhard sold 500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $110.26, for a total value of $55,130.00. Following the sale, the director directly owned 8,000 shares of the company’s stock, valued at $882,080. The trade was a 5.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have bought 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. Company insiders own 18.26% of the company’s stock.

Institutional Investors Weigh In On Inhibrx Biosciences

Several large investors have recently modified their holdings of the stock. HighTower Advisors LLC lifted its holdings in shares of Inhibrx Biosciences by 1.6% during the third quarter. HighTower Advisors LLC now owns 884,441 shares of the company’s stock worth $88,515,000 after purchasing an additional 13,890 shares during the period. Bank of America Corp DE purchased a new position in Inhibrx Biosciences in the 2nd quarter valued at $79,698,000. BlackRock Inc. acquired a new position in Inhibrx Biosciences in the 2nd quarter valued at $78,261,000. Parkman Healthcare Partners LLC acquired a new position in Inhibrx Biosciences in the 2nd quarter valued at $24,346,000. Finally, Soleus Capital Management L.P. acquired a new position in Inhibrx Biosciences in the 3rd quarter valued at $21,017,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Further Reading

Analyst Recommendations for Inhibrx Biosciences (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.